[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-32292":3,"doc-seo-32292":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},32292,962075114101,"Seraphina","https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165",7,"Healthcare","From Efficacy to Access in Long-Acting HIV Therapy","The article examines how long-acting injectable antiretroviral therapy can translate the clinical success of ART into real-world treatment success for people facing structural or behavioral barriers to daily medication adherence. It describes the LATITUDE trial’s two-step design: oral ART with adherence support and incentives, followed by random assignment to continued oral therapy or injections of long-acting cabotegravir–rilpivirine. It defines regimen failure endpoints and notes the central question of whether separating viral suppression from daily pill use improves outcomes.","cbCaio58JLlBZnVg","https://ap.wps.com/l/cbCaio58JLlBZnVg","pdf",332847,1,3,"English","en","# LATITUDE trial design\n## Step 1: Oral ART with support\n## Step 2: Randomization to injections vs oral therapy\n# Outcomes and endpoints\n## Primary outcome: Regimen failure\n## Secondary outcomes","[{\"question\":\"What problem does the article address about long-term HIV treatment?\",\"answer\":\"Despite highly effective ART, durable viral suppression can remain difficult for people with adherence barriers. Long-acting injectable ART is discussed as a way to extend benefits to populations who struggle with daily oral therapy.\"},{\"question\":\"How is the LATITUDE trial structured?\",\"answer\":\"Participants begin with standard oral ART plus adherence support and economic incentives (step 1). They then enter random assignment (step 2) to either continue oral ART or switch to long-acting cabotegravir–rilpivirine injections.\"},{\"question\":\"What is the primary outcome used in the trial?\",\"answer\":\"Regimen failure, defined as the earliest occurrence of confirmed virologic failure (two consecutive HIV-1 RNA measurements \\u003e200 copies/mL after randomization) or permanent discontinuation of the trial regimen.\"}]",1781044410,8,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":83,"head_meta":85,"extra_data":87,"updated_unix":25},105,"from-efficacy-to-access-in-long-acting-hiv-therapy","",{"@graph":34,"@context":82},[35,51,65],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,48],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":20},"https://docshare.wps.com/document/healthcare/",{"item":49,"name":13,"@type":41,"position":50},"https://docshare.wps.com/document/from-efficacy-to-access-in-long-acting-hiv-therapy/32292/",4,{"url":49,"name":13,"@type":52,"author":53,"headline":13,"publisher":55,"fileFormat":58,"description":14,"dateModified":59,"datePublished":59,"encodingFormat":58,"isAccessibleForFree":60,"interactionStatistic":61},"DigitalDocument",{"name":9,"@type":54},"Person",{"url":39,"name":56,"@type":57},"DocShare","Organization","application/pdf","2026-06-09",true,{"@type":62,"interactionType":63,"userInteractionCount":4},"InteractionCounter",{"@type":64},"ViewAction",{"@type":66,"mainEntity":67},"FAQPage",[68,74,78],{"name":69,"@type":70,"acceptedAnswer":71},"What problem does the article address about long-term HIV treatment?","Question",{"text":72,"@type":73},"Despite highly effective ART, durable viral suppression can remain difficult for people with adherence barriers. Long-acting injectable ART is discussed as a way to extend benefits to populations who struggle with daily oral therapy.","Answer",{"name":75,"@type":70,"acceptedAnswer":76},"How is the LATITUDE trial structured?",{"text":77,"@type":73},"Participants begin with standard oral ART plus adherence support and economic incentives (step 1). They then enter random assignment (step 2) to either continue oral ART or switch to long-acting cabotegravir–rilpivirine injections.",{"name":79,"@type":70,"acceptedAnswer":80},"What is the primary outcome used in the trial?",{"text":81,"@type":73},"Regimen failure, defined as the earliest occurrence of confirmed virologic failure (two consecutive HIV-1 RNA measurements >200 copies/mL after randomization) or permanent discontinuation of the trial regimen.","https://schema.org",{"og:url":49,"og:type":84,"og:title":13,"og:site_name":56,"og:description":14},"article",{"robots":86,"canonical":49},"index,follow",{"doc_id":7,"site_id":30}]